Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
82
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report

Tong Zhao1 Department of Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of ChinaView further author information
,
Yuqin Tian2 Department of Care Operations, The Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of ChinaView further author information
,
Xinjia Ding3 Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of ChinaView further author information
,
Lin Liu4 Navy Qingdao Special Care Center, Qingdao, 266071, People’s Republic of ChinaView further author information
,
Bowen Tan5 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of ChinaView further author information
,
Bin Yang5 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of ChinaView further author information
,
Jianlin Wu5 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of ChinaView further author information
,
Ting Lei6 Department of Thoracic Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of ChinaView further author information
,
Ruoyu Wang2 Department of Care Operations, The Affiliated Hospital of Qingdao University, Qingdao, People’s Republic of ChinaView further author information
&
Yan Ding5 The Institute for Translational Medicine, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of China;7 Department of Pediatrics, Children’s Hospital of Boston, Harvard Medical School, Boston, MA, 02115, USACorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-7708-4391View further author information
ORCID Icon show all
Pages 2839-2845 | Published online: 28 Apr 2021

References

  • Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007;16(3):566–571. doi:10.1158/1055-9965.EPI-06-0782
  • Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37. doi:10.1634/theoncologist.12-1-20
  • Fujita S, Masago K, Takeshita J, et al. Multiple primary malignancies in patients with non-small cell lung cancer. Intern Med. 2015;54(3):325–331. doi:10.2169/internalmedicine.54.2921
  • Afghahi A, Sledge GW. Targeted Therapy for Cancer in the Genomic Era. Cancer J. 2015;21(4):294–298. doi:10.1097/PPO.0000000000000135
  • Filipits M. New developments in the treatment of squamous cell lung cancer. CurrOpinOncol. 2014;26(2):152–158.
  • The Cancer Genome Atlas Research Network. Comprehensive genomic and characterization of squamous cell lung cancers. Nature. 2012;489:519–525. doi:10.1038/nature11404
  • Monnet I, Audigier-Valette C, Girard N, et al. Real-life effectiveness of Erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: results of the PEPiTA observational study. Lung Cancer. 2016;98:84–90. doi:10.1016/j.lungcan.2016.05.016
  • Peters S, Stahel RA, Dafni U, et al. EMPHASIS-lung Collaborative Group.Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. 2017;12(4):752–762.
  • Paik PK, Varghese AM, Sima CS, et al. Response to Erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther. 2012;11(11):2535–2540. doi:10.1158/1535-7163.MCT-12-0163
  • Vansteenkiste JF, Canon JL, De Braud F, et al. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: results from the Phase II BASALT-1 Study. J Thorac Oncol. 2015;10(9):1319–1327. doi:10.1097/JTO.0000000000000607
  • Adjei AA, Bennouna J, Leighl NB, et al. Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies. J Clin Oncol. 2016;34(15_suppl.):e20522. doi:10.1200/JCO.2016.34.15_suppl.e20522
  • Lara PN, Longmate J, Mack PC, et al. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015;21(19):4321–4326. doi:10.1158/1078-0432.CCR-14-3281
  • Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 Study: a Biomarker-IntegratedTargeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(30):3638–3647. doi:10.1200/JCO.2015.66.0084
  • Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Renal Physiol. 2017;313(2):F145–F154. doi:10.1152/ajprenal.00480.2016
  • McKay RR, De Velasco G, Werner L, et al. A Phase 1 study of Buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016;122(15):2389–2398. doi:10.1002/cncr.30056
  • Jonasch E, Hasanov E, Corn PG, et al. A randomized Phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017;28(4):804–808. doi:10.1093/annonc/mdw676

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.